Cohance Lifesciences Releases Integrated Annual Report 2026
Cohance Lifesciences Ltd has filed its Integrated Annual Report and Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report, compliant with the Companies Act, 2013 and SEBI Listing Regulations, is being disseminated electronically to members. The company highlights FY26 as a year of transition, marked by investments in future capabilities, integration of scientific legacies, new therapeutic platforms, and a strengthened leadership structure. Challenges faced included customer-led inventory normalization, commercial-order phasing, and regulatory/operational hurdles. The report emphasizes Cohance's role at the intersection of pharmaceutical innovation and global healthcare delivery, focusing on advancing the science of progress through chemistry and molecular complexity.
Key Highlights
- Annual Report 2025-26 filed, including BRSR and AGM notice.
- FY26 described as a year of transition and investment in future capabilities.
- Company faced challenges like inventory normalization and operational hurdles.
- Focus remains on pharmaceutical innovation and healthcare delivery.
- Report available on the company website and sent electronically to members.
Price Impact
More from COHANCE